You just read:

Journal of Clinical Psychiatry Publishes Data from Alkermes' Phase 3 ENLIGHTEN-1 Efficacy Study of ALKS 3831 in Patients With Schizophrenia

News provided by

Alkermes plc

04 Mar, 2020, 12:00 GMT